Tetra Therapeutics, a clinical stage biopharmaceutical company focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, notably BPN14770, a selective inhibitor of phosphodiesterase‐4D (PDE4D), announced changes to its executive team as the company marks one year since the close of its merger with Shionogi & Co., Ltd.. Tetra Therapeutics currently operates as a wholly owned subsidiary of Shionogi.
After a distinguished career in biotechnology, including the founding of Tetra, Mark Gurney, has announced his retirement as Chief Executive Officer (CEO), effective June 30, 2021. After his departure, Mr. Gurney will continue to serve as a consultant and advisor to Tetra Therapeutics for a transitory period to ensure a smooth succession process and continued advancement of Tetra’s pipeline.
Read more on the Business Wire website.